Literature DB >> 11403226

Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

M Gupta1, G J Noel, M Schaefer, D Friedman, J Bussel, R Johann-Liang.   

Abstract

Intravenous immune gamma-globulin (IVIG) is used successfully in the treatment of Kawasaki disease, with dose-dependent rapid resolution of symptoms such as fever and irritability and a decrease in ESR, WBCs, and platelets. The mode of action of IVIG in reducing this inflammatory response is not clearly understood. Recently anticytokine antibodies in IVIG have been demonstrated. Serum levels of proinflammatory cytokines have been shown to be elevated in patients with Kawasaki disease. The cytokine interleukin-6 (IL-6) is involved in the de novo production of acute-phase proteins by hepatocytes and cause thrombocytosis and fever in response to tissue injury. Patients receiving parenteral recombinant human IL-6 have dose-dependently experienced fever, malaise, chills, and acute-phase reaction. With high IL-6 concentrations, central nervous system toxicity has also been reported and IL-6 has been thought to mediate endothelial damage. We evaluated the response of stimulated blood cells of 12 normal children to IVIG in the release of the cytokines IL-6, IL-8, TNF-alpha. and IL-6 receptor (sIL-6R). The levels of cytokines IL-6, IL-8, and TNF-alpha (but not sIL-6R) in peripheral blood induced by stimulation with LPS were markedly reduced (P < 0.008) within 3 hr when incubated with IVIG compared to without IVIG. Thus we demonstrated that cells of normal children respond to IVIG in vitro by reducing cytokines such as IL-8, TNF-alpha, and IL-6 without affecting the level of receptor sIL-6R during an acute inflammatory response. We also found significantly higher IL-6 levels in children with Kawasaki disease compared to children with blood culture-negative febrile illnesses. In five children with Kawasaki disease we measured serum IL-6 before and after IVIG and assessed the clinical response to IVIG therapy. Therapy with IVIG was followed by a rapid resolution of symptoms in Kawasaki disease, with a significant decrease in serum IL-6. The attenuation of proinflammatory cytokine responses, especially IL-6, following infusions of IVIG may play an integral role in the rapid resolution of symptoms and decrease in the acute-phase proteins in children with Kawasaki disease. Cells of normal children were found to respond to the IVIG in a manner similar to that of the Kawasaki children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403226     DOI: 10.1023/a:1011039216251

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  Evaluation of the cytokine response in Kawasaki disease.

Authors:  B A Eberhard; U Andersson; R M Laxer; V Rose; E D Silverman
Journal:  Pediatr Infect Dis J       Date:  1995-03       Impact factor: 2.129

2.  Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease.

Authors:  H Suzuki; S Uemura; S Tone; T Iizuka; M Koike; K Hirayama; J Maeda
Journal:  Eur J Pediatr       Date:  1996-04       Impact factor: 3.183

3.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

Review 4.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 5.  Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors:  Y Abe; A Horiuchi; M Miyake; S Kimura
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

6.  Modulation of mononuclear phagocyte function by intravenous gamma-globulin.

Authors:  R P Kimberly; J E Salmon; J B Bussel; M K Crow; M W Hilgartner
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

7.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.

Authors:  P Aukrust; S S Frøland; N B Liabakk; F Müller; I Nordøy; C Haug; T Espevik
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

9.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

10.  Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

Authors:  J M Stouthard; H Goey; E G de Vries; P H de Mulder; A Groenewegen; L Pronk; G Stoter; H P Sauerwein; P J Bakker; C H Veenhof
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more
  27 in total

Review 1.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 2.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

4.  High serum hepcidin is associated with the occurrence of anemia in anti-myeloperoxidase antibody-associated vasculitis with normal kidney function: a cross-sectional study.

Authors:  Tong Chen; Peng-Cheng Xu; Shui-Yi Hu; Shan Gao; Jun-Ya Jia; Tie-Kun Yan
Journal:  Rheumatol Int       Date:  2019-03-29       Impact factor: 2.631

Review 5.  Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Authors:  Luanna Yang; Eveline Y Wu; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

6.  Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease.

Authors:  Ho-Chang Kuo; Ya-Ling Yang; Jiin-Haur Chuang; Mao-Meng Tiao; Hong-Ren Yu; Li-Tung Huang; Kuender D Yang; Wei-Chiao Chang; Chiu-Ping Lee; Ying-Hsien Huang
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

7.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

Review 8.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

9.  Thrombocytopenia as a presenting feature of Kawasaki disease: a case series from North India.

Authors:  Surjit Singh; Deepali Gupta; Deepti Suri; Rohit Manoj Kumar; Jasmina Ahluwalia; Reena Das; Neelam Varma
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

10.  Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in kawasaki disease.

Authors:  Goh-Woon Lim; Mina Lee; Hae Soon Kim; Young Mi Hong; Sejung Sohn
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.